UChicagoCancerCenter
@UCCancerCenter
Followers
10K
Following
9K
Media
4K
Statuses
14K
A Comprehensive Cancer Center designated by @theNCI for 50+ yrs. #NothingWillStopUs #NCIDesignated #UChiCancer50 @UCMOCECHE https://t.co/RDULLZ8a8j
Chicago, IL
Joined June 2010
Check out the excellent perspective published by Sean Pitroda, MD, and colleagues in @NatureGenet, highlighting how high aneuploidy scores predict immunotherapy response and can help guide personalized cancer treatment. @UChicagoRadonc @UChicagoMed.
0
3
7
RT @SeanPitroda: 📢 New in Cancer Cell: Radiotherapy is essential for local control—but can it unintentionally accelerate growth of distant….
0
42
0
Thrilled to welcome Jeff Rathmell, PhD! Exciting developments are already underway!! @JeffRathmell @Ludwig_Cancer @UChicagoBSD.
I'm excited to start at @UCCancerCenter as chair of the Ben May Dept for Cancer Research and the @Ludwig_Cancer of UChicago! Things are moving already & we launched a faculty search for tumor microenvironment--take a look & apply!.
0
0
4
RT @UChicagoMed: Brain tumors are rare, scary and can be quite serious. Learn more about our approach to personalized care at the Brain and….
0
2
0
RT @UChicagoLeuk: Congrats to co-editor/author @Anand_88_Patel and chapter author @michaelwd_hem on the release of the.@ASH_hematology Self….
0
2
0
RT @LiamSpurrMD: Check out our new perspective in @NatureGenet exploring the role of #aneuploidy in predicting outcomes following treatment….
0
4
0
🌟 In a new study, Huang et al., emphasizes on combining immunotherapy with radiation that may overcome therapy resistance in patients with high aneuploidy scores, offering a new strategy for personalizing therapy. @SeanPitroda @UChicagoRadonc @NatureGenet
1
3
4
Join today's speaker, Brandon Faubert, PhD, as he shares the insights on in-vivo tumor metabolism and how it helps identify the metabolic programs of tumor progression. 📅 6/30/2025.⏰ 10 AM
0
0
5
In a recent article, Ari Rosenberg, MD, and Everett Vokes, MD, discuss the promise and complexities of the KEYNOTE-689 trial, which shows event-free survival benefits from pembrolizumab in curative-intent settings. @AriRosenbergMD @eevokes @NEJM.
1
3
11
RT @DAVAOnc: Dr. Ari Rosenberg (@AriRosenbergMD) @UChicagoMed highlighted early-phase findings for CRB-701, a site-specific Nectin-4 ADC in….
0
4
0
RT @UChicagoHemOnc: A BIG congratulations to 3rd year @UCHemOncFellows Dr. @AlexandraRojek who was just named a 2025 recipient of the @Damo….
0
4
0
RT @MPI_Biochem: An interdisciplinary study @labs_mann & @uchicago_obgyn uncovers how benign borderline ovarian tumors develop into invasiv….
0
9
0
RT @OvCa_UChicago: New from the Lengyel/Kenny Lab: our study in @Cancer_Cell with @labs_mann charts how borderline ovarian tumors evolve in….
0
5
0
RT @ErnstLengyel: Proud to share our latest work now in @Cancer_Cell. In collaboration with @MPI_Biochem, we map the progression from borde….
0
13
0
RT @UChicagoLeuk: check out this new manuscript featuring @DrWendyStock as co-author that looks at cytarabine pharmacogenomics in children/….
0
2
0
A new study in @JAMANetworkOpen evaluates the barriers that prevent patients from racial and ethnic minority groups from participating in #clinicaltrials for #breastcancer.
0
0
4
Faculty and trainees from @UCCancerCenter presented latest data from groundbreaking clinical studies at the 2025 ASCO annual meeting, the world's premier oncology conference. @UChicagoMed @UChicagoHemOnc @UChicagoPHS.Check out the highlights here 👇.
0
3
6
Radiation therapy: a double-edged sword. A recently published Nature paper by Ralph Weichselbaum, MD, reveals that high doses of radiation may promote growth of metastatic tumors. @rweichselbaum @AndrasPiffko @SeanPitroda. @UChicagoRadonc @Ludwig_Cancer.
3
5
13
RT @TargetedOnc: Panelists discuss how future directions in #cGVHD management may include preemptive use of targeted therapies, first-line….
0
2
0
RT @UChicagoHemOnc: Our amazing social workers Julie & Stephanie from the Supportive Oncology team presented last week at the Association f….
0
3
0